Evidence map›Paper›PMID 28448739›Full record

ArticleHuman vaccines & immunotherapeutics2017

Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.

Xiaoqing Cheng, Yueyuan Zhao, Xuefeng Zhang, Hui Jin, Jie Min

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. [Vaccines against hepatitis E virus: state of development].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2022
    Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoqing Chenga Department of Epidemiology and Health Statistics , School of Public Health, Southeast University , Nanjing , China.
Yueyuan Zhaoc Lianyungang City's Center for Disease Control and Prevention , Lianyungan , China.
Xuefeng Zhangd Jiangsu Provincial Center for Disease Control and Prevention , Nanjing , China.
Hui Jina Department of Epidemiology and Health Statistics , School of Public Health, Southeast University , Nanjing , China.ORCID 0000-0002-5441-1652
Jie Mina Department of Epidemiology and Health Statistics , School of Public Health, Southeast University , Nanjing , China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective This study was conducted to assess the cost-effectiveness of hepatitis E vaccination of elderly population in the sporadic regions in China. Methods We used a decision tree-Markov model to evaluate the cost-effectiveness of 3 kinds of hepatitis E virus vaccination strategies from societal perspectives. Parameter estimates were obtained from published researches and experts' opinion. The time horizon was 16 years, and the discounted rate was 3% annually. Costs are expressed in 2016 US dollars. Results The universal vaccination strategy had an incremental cost-effectiveness ratio (ICER) of US$ 8475.90 per QALY gained versus no vaccination. The implementation of screening and vaccination strategy would have an ICER of US$ 4044.28, compared with no vaccination. The vaccination was cost-effective (ICER< 3 times China's per capital gross domestic product/quality-adjusted life years). The QALY of asymptomatic infection, vaccine coverage and vaccine protection are the important parameters impacting the ICER in one-way sensitivity analysis and screening and vaccination being the dominant strategy in probabilistic sensitivity analysis. Conclusion This analysis indicates that screening and vaccination is the most cost-effective hepatitis E intervention strategy of elderly population in sporadic region in China.

Indexed as

AgedChinaCost-Benefit AnalysisFemaleHepatitis EHepatitis E virusHumansImmunization ProgramsMaleMarkov ChainsVaccinationViral Hepatitis VaccinesViral Hepatitis VaccinesCost-effectiveness analysisEconomic evaluationElderly populationHepatitis E vaccines

Identifiers

PMID28448739
PMCPMC5557228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.